Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Agnès Veyradier

Showing results (1-10 of 138) with videos related to

Pageof 14
Sort By:
Current Opinion in Critical Care|September 30, 2015
Thrombotic thrombocytopenic purpura: from diagnosis to therapyEric Mariotte, Agnès Veyradier
Presse Medicale (Paris, France : 1983)|January 24, 2012
Current management and therapeutical perspectives in thrombotic thrombocytopenic purpuraPaul Coppo, Agnès Veyradier
Medecine Sciences : M/S|December 24, 2011
[ADAMTS13, von Willebrand factor specific cleaving protease]Agnès Veyradier, Paul Coppo
Cardiovascular & Hematological Disorders Drug Targets|March 12, 2009
Thrombotic microangiopathies: towards a pathophysiology-based classificationPaul Coppo, Agnès Veyradier
Seminars in Hematology|January 17, 2004
Assays of ADAMTS-13 activityAgnès Veyradier, Jean-Pierre Girma
Presse Medicale (Paris, France : 1983)|December 13, 2006
[Acquired idiopathic thrombotic thrombocytopenic purpura: arguments for an autoimmune disease]Paul Coppo, Agnès Veyradier, Matthieu Monge, et al.
Current Opinion in Hematology|August 3, 2020
Insights into ADAMTS13 structure: impact on thrombotic thrombocytopenic purpura diagnosis and managementElien Roose, Agnès Veyradier, Karen Vanhoorelbeke
Current Opinion in Pediatrics|February 21, 2013
Thrombotic thrombocytopenic purpura in childrenChantal Loirat, Paul Coppo, Agnès Veyradier
Journal of Thrombosis and Haemostasis : JTH|November 25, 2020
Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive caplacizumab?Adrien Picod, Agnès Veyradier, Paul Coppo
Expert Review of Hematology|May 21, 2019
An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpuraBérangère S Joly, Paul Coppo, Agnès Veyradier
Pageof 14

Showing results (1-10 of 138) with videos related to

Sort By:
Pageof 14
Current Opinion in Critical Care|September 30, 2015
Thrombotic thrombocytopenic purpura: from diagnosis to therapyEric Mariotte, Agnès Veyradier
Presse Medicale (Paris, France : 1983)|January 24, 2012
Current management and therapeutical perspectives in thrombotic thrombocytopenic purpuraPaul Coppo, Agnès Veyradier
Medecine Sciences : M/S|December 24, 2011
[ADAMTS13, von Willebrand factor specific cleaving protease]Agnès Veyradier, Paul Coppo
Cardiovascular & Hematological Disorders Drug Targets|March 12, 2009
Thrombotic microangiopathies: towards a pathophysiology-based classificationPaul Coppo, Agnès Veyradier
Seminars in Hematology|January 17, 2004
Assays of ADAMTS-13 activityAgnès Veyradier, Jean-Pierre Girma
Presse Medicale (Paris, France : 1983)|December 13, 2006
[Acquired idiopathic thrombotic thrombocytopenic purpura: arguments for an autoimmune disease]Paul Coppo, Agnès Veyradier, Matthieu Monge, et al.
Current Opinion in Hematology|August 3, 2020
Insights into ADAMTS13 structure: impact on thrombotic thrombocytopenic purpura diagnosis and managementElien Roose, Agnès Veyradier, Karen Vanhoorelbeke
Current Opinion in Pediatrics|February 21, 2013
Thrombotic thrombocytopenic purpura in childrenChantal Loirat, Paul Coppo, Agnès Veyradier
Journal of Thrombosis and Haemostasis : JTH|November 25, 2020
Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive caplacizumab?Adrien Picod, Agnès Veyradier, Paul Coppo
Expert Review of Hematology|May 21, 2019
An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpuraBérangère S Joly, Paul Coppo, Agnès Veyradier
Pageof 14